Header Logo

Search Result Details

Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
OVERMAN, MICHAEL JAMES
One or more keywords matched the following items that are connected to OVERMAN, MICHAEL JAMES
Item TypeName
Academic Article Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases.
Academic Article Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?
Academic Article Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance.
Academic Article The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer.
Academic Article Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater
Academic Article Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study.
Academic Article Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab.
Academic Article The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia.
Academic Article Bevacizumab as a chemoprotectant: reducing oxaliplatin induced hepatic sinusoidal injury.
Concept Bevacizumab
Academic Article FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival.
Academic Article Bevacizumab Does Not Influence the Efficacy of Partial Splenic Embolization in the Management of Chemotherapy-Induced Hypersplenism.
Academic Article Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma.
Search Criteria
  • Bevacizumab